Skip to content

DMT (N,N-Dimethyltryptamine)

A short-acting psychedelic studied for its acute effects on perception and its therapeutic potential.

State of the evidence

Synthesized

Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for DMT, dimethyltryptamine, 5-MeO-DMT, then ranked by relevance.

DMT is a fast-acting serotonergic psychedelic that produces intense, short-lived altered states of consciousness characterized by ego dissolution, mystical-type experiences, and subjective features resembling near-death experiences. Neuroimaging studies show DMT reduces alpha/beta oscillatory power, increases signal diversity, and globally reorganizes brain functional connectivity. Evidence from small, mostly open-label trials suggests potential antidepressant and anxiolytic effects lasting days to months, but the overall evidence base remains limited by small samples, lack of blinding, and early-stage designs.

Confidence in the evidence

Low-Moderate
  • Most human studies are small (N=9-28) and many are open-label or non-blind, increasing risk of bias.
  • Neuroimaging and subjective effects are consistent across multiple studies, but therapeutic evidence is preliminary and from few trials.
  • Preclinical and mechanistic studies (sigma-1, 5-HT2A, neurogenesis) are numerous but translational relevance is uncertain.
  • Registry review confirms the field is dominated by early-phase trials with conservative eligibility criteria.
How we rate confidence

Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.

Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.

Evidence by study

Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.

The Hallucinogen N,N -Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator 2009
Supports

DMT binds sigma-1 receptors and inhibits sodium channels; DMT-induced hypermobility in mice is sigma-1 dependent.

experimental (animal + cell)

Dose-Response Study of N,N-Dimethyltryptamine in Humans 1994
Supports

IV DMT produced rapid, dose-dependent hallucinogenic effects peaking at 90-120 seconds and resolving by 30 minutes.

RCT (within-subject, double-blind) Sample size: 12

Neural correlates of the DMT experience assessed with multivariate EEG. 2019
Supports

DMT reduced alpha/beta power and increased signal diversity in EEG; delta/theta activity correlated with peak visual experience.

RCT (within-subject, placebo-controlled) Sample size: 13

Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. 2020
Supports

DMT potency in mouse head-twitch response strongly correlates with human hallucinogenic potency (r=0.94), supporting 5-HT2A mediation.

experimental (animal + correlational)

Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT 2019
Supports

DMT-occasioned God encounters were phenomenologically similar to non-drug experiences, often described as encounters with 'Ultimate Reality' and meeting criteria for complete mystical experience.

observational (survey) Sample size: 606

Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids 2006
Mixed

Ayahuasca has a safety margin comparable to codeine; acute psychological risks include transient psychotic episodes, but no evidence of sustained abuse potential.

review

DMT Models the Near-Death Experience 2018
Supports

DMT produced significant increases in near-death experience phenomenology compared to placebo, with striking similarity to actual NDEs.

RCT (within-subject, placebo-controlled) Sample size: 13

Human brain effects of DMT assessed via EEG-fMRI. 2023
Supports

DMT increased global functional connectivity, network disintegration, and compressed the principal cortical gradient; effects correlated with 5-HT2A receptor distribution.

RCT (within-subject, placebo-controlled) Sample size: 20

A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms. 2019
Supports

A single inhalation of 5-MeO-DMT vapor was associated with sustained enhancement of life satisfaction and mindfulness, and reduction of psychopathological symptoms.

observational (naturalistic)

Psychological Effects of (S)-Ketamine and N,N-Dimethyltryptamine (DMT): A Double-Blind, Cross-Over Study in Healthy Volunteers 2005
Mixed

DMT and (S)-ketamine produced similar global intensity, but DMT induced stronger positive symptoms (thought disorder, inappropriate affect) while ketamine induced stronger negative symptoms.

RCT (double-blind, cross-over) Sample size: 9

Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells. 2014
Supports

DMT and 5-MeO-DMT inhibited pro-inflammatory cytokines and promoted anti-inflammatory IL-10 via sigma-1 receptor in human dendritic cells.

experimental (in vitro)

Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by l‐tryptophan or 5‐methoxy‐N,N‐dimethyltryptamine in rats treated with a monoamine oxidase inhibitor 1971
Supports

5-MeO-DMT produced hyperactivity in rats that was inhibited by chlorpromazine, suggesting serotonin receptor mediation.

experimental (animal)

N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function 2018
Unclear

DMT is an endogenous compound with biosynthesis in brain and periphery; its natural physiological role remains unresolved and distinct from effects of exogenous administration.

review

Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. 2010
Unclear

5-MeO-DMT is metabolized by MAO-A and CYP2D6; co-administration with MAO inhibitors (e.g., harmaline) increases exposure and risk of serotonin toxicity.

review

Making "bad trips" good: How users of psychedelics narratively transform challenging trips into valuable experiences. 2021
Mixed

Bad trips are common but often narratively transformed into valuable, life-altering experiences through storytelling and integration.

qualitative Sample size: 50

Therapeutic properties of ayahuasca component N,N-Dimethyltryptamine in a pre-clinical model of Parkinson's disease. 2026
Supports

DMT reduced neuroinflammation and preserved neurons in the nigrostriatal pathway, with behavioral improvements in a Parkinson's model.

experimental (animal)

Combined DMT-harmine formulation reduces negative self-referential emotions during social self-evaluation: a randomized placebo-controlled trial in healthy volunteers. 2026
Supports

Combined harmine+DMT significantly reduced embarrassment during self-evaluation compared to placebo, with no significant effect of harmine alone.

RCT (double-blind, placebo-controlled, cross-over) Sample size: 28

Advancing Next-Generation Psychedelic Therapeutics through Selective 5-HT2A Activation, Precision Aerosol Delivery, and Optimized 5-MeO-DMT Treatment Paradigms 2026
Unclear

Patent applications describe selective 5-HT2A activators, aerosol delivery, and structured 5-MeO-DMT regimens for depression, indicating a trend toward scalable psychedelic therapeutics.

theoretical/patent review

ProliferativeEffects of the Psychedelic N,N-Dimethyltryptamine(DMT) in Human Neural Stem Cells 2026
Supports

24-hour DMT exposure increased human neural stem cell proliferation in a concentration-dependent manner and upregulated BDNF expression.

experimental (in vitro)

Proliferative Effects of the Psychedelic N,N-Dimethyltryptamine (DMT) in Human Neural Stem Cells. 2026
Supports

DMT increased proliferation and BDNF expression in human neural stem cells at concentrations consistent with plasticity effects.

experimental (in vitro)

Beyond symptom reduction: DMT improves anxiety, life satisfaction, and quality of life in healthy volunteers and patients with depression 2026
Supports

Inhaled DMT reduced state anxiety up to 1 day and increased life satisfaction up to 14 days in healthy volunteers; patients showed improved quality of life up to 12 months.

open-label trial Sample size: 41

DMT and Microtubule Coherence Selection: A Testable Model of Informational Throttling in Time Perception 2026
Unclear

A theoretical model proposes DMT alters time perception by modulating microtubule vibrational coherence via 5-HT2A and sigma-1 receptors.

theoretical

N,N-dimethyltryptamine elicits antidepressant and anxiolytic effects in helpless mice: a comparative study with S-ketamine. 2026
Supports

DMT (10 mg/kg) produced rapid and long-lasting antidepressant and anxiolytic effects in helpless mice, comparable to S-ketamine, with effects lasting up to 8 days.

experimental (animal)

DMT und Ayahuasca / DMT and Ayahuasca 2026
Unclear

A transdisciplinary review covering DMT and ayahuasca across eight disciplines, noting unique features: oral inactivity without MAO-I, ultra-short duration, endogenous occurrence, and legal status.

review

Registered Clinical Trials of Ayahuasca and DMT: A Scoping Review. 2026
Unclear

The DMT/ayahuasca trial landscape is dominated by early-phase, academically sponsored studies with conservative eligibility criteria and a focus on safety and subjective effects.

scoping review

Points of agreement

  • DMT produces rapid, intense, short-lived altered states with consistent EEG and fMRI signatures (reduced alpha/beta, increased signal diversity, global connectivity changes).
  • DMT acts primarily via 5-HT2A receptors, with additional sigma-1 receptor binding contributing to neuroimmunomodulatory and neuroplastic effects.
  • Preclinical studies consistently show DMT has antidepressant and anxiolytic potential in animal models, with effects lasting days.
  • Human studies report sustained improvements in well-being, life satisfaction, and reduced anxiety after DMT administration, though most are open-label.

Conflicts

  • One study found DMT and (S)-ketamine produce different symptom profiles (positive vs. negative schizophrenia-like symptoms), suggesting distinct models of psychosis.
  • The natural physiological role of endogenous DMT remains unclear and may differ from effects of exogenous administration.
  • Qualitative data show bad trips are common but often reframed as valuable, while clinical trials emphasize safety and positive outcomes.

Gaps

  • Lack of large, double-blind, placebo-controlled trials with adequate blinding for therapeutic outcomes.
  • Durability of antidepressant/anxiolytic effects beyond 12 months is only assessed in one small open-label study.
  • Dose-response relationships and optimal administration routes (IV, inhaled, oral with MAO-I) are not systematically compared.
  • Effects in diverse populations (e.g., women, older adults, comorbid conditions) are largely unstudied.
  • Mechanistic link between acute subjective effects and long-term therapeutic changes is not established.
Browse these studies in the library
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is DMT, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when DMT or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

Ask your own question in the Research Synthesis Tool

Latest monthly recap: June 2026 →

1,465 articles · 485 from the last two years · 3,314,873 participants across 403 studies reporting sample size

Common study designs

review 285 systematic review 61 experimental study 197 observational cohort 56 theoretical or philosophical paper 86

Research

Synthesize the evidence → Search all →

New insights into the clinical and nonclinical effects of psychedelic substances: an integrative review

Matthias Forstmann, Christina Sagioglou preprint

After a long period of stagnation, research on psychedelic substances like LSD, psilocybin, and DMT has revived over the last decade, with major programs in Europe and the United States. This review summarizes recent insights into their potential for treating mental health disorders, effects on recreational users, and underlying neurological and cognitive processes. It covers the history of psychedelic research, objective and subjective effects, prevalence and correlates of use, and potential for harm. The review examines clinical benefits for major depression, anxiety, and substance use disorders, along with proposed neural and cognitive mechanisms. It also discusses effects on healthy subjects, including psychological wellbeing, personality changes, nature relatedness, and creativity, and concludes with long-term effects of single experiences.

DOI: 10.31234/osf.io/2489x

Psychedelics Use and the Risk of Reduced Formal Mental Health Care

Research Square Sean Viña

People who use psychedelics are less likely to seek formal mental health care, including medication and outpatient treatment, even when experiencing high psychological distress. Analyzing data from over 458,000 participants in a national US survey between 2010 and 2018, the study found that as distress levels increase, psychedelic users become even less inclined to use formal care compared to non-users. This suggests a heightened risk of self-medication as psychedelics become more culturally and legally accepted.

DOI: 10.21203/rs.3.rs-4378944/v1

Meditation, Psychedelics, and Brain Connectivity: A Randomised Controlled Resting-State fMRI Study of N,N -Dimethyltryptamine and Harmine in a Meditation Retreat

medRxiv Klemens Egger, Daniel Meling, Firuze Polat et al. preprint

In a double-blind, placebo-controlled pharmaco-fMRI study, 40 meditation practitioners on a three-day retreat received either placebo or buccal DMT-harmine (120 mg each). Meditation alone increased network segregation across several resting-state networks, while DMT-harmine increased functional connectivity within the visual network and between visual and attention networks. Between-group differences showed increased connectivity between visual and salience networks in the DMT-harmine group. No prolonged cortical gradient disruption was observed, indicating a return to typical brain organization shortly after the experience. Meditation reduced connectivity between networks, whereas DMT-harmine increased within- and between-network connectivity, revealing distinct neural mechanisms.

DOI: 10.1101/2025.07.30.25332422

PHARMACOKINETICS OF N,N-DIMETHYLTRYPTAMINE FUMARATE IN HUMANS

Meghan Good, Tiffanie Benway, Zelah Joel et al. 4 citations

DMT (N,N-dimethyltryptamine) is being developed as a treatment for major depressive disorder. In a phase I trial, 24 healthy adults received escalating intravenous doses of DMT fumarate (SPL026) that were safe and well-tolerated. DMT exposure increased proportionally with dose over the 9–21.5 mg range. Peak plasma concentration occurred at about 10 minutes, and the mean elimination half-life was 9–12 minutes. In vitro experiments showed that DMT is cleared by monoamine oxidase A (MAO-A) and modified by the enzymes CYP2D6 and CYP2C19. The unbound fraction of DMT in plasma was approximately 70%. These findings support the development of DMT infusion regimens for treating major depressive disorder.

DOI: 10.22541/au.165237523.39763980/v1

Rapid Isolation and High-Purity Characterization of N, N-Dimethyltryptamine from Mimosa tenuiflora for Analytical Standard Development and Regulatory Insight

Zhang Ming

A rapid and straightforward method for extracting the psychedelic compound DMT from the inner bark of Mimosa tenuiflora was developed, yielding a reference chemical suitable for chromatography. The isolated compound's identity was confirmed through mass spectrometry, NMR spectroscopy, melting-point analysis, and FTIR, with results matching earlier reports. UV absorption spectrometry indicated purity above 95% compared to a standard tryptamine reference. Creating accessible analytical standards can support controlled scientific research, improve forensic and pharmaceutical drug identification and quality control, and inform regulatory policies.

DOI: 10.2139/ssrn.7079544

Born Twice DMT and the Echo of Our First Conscious Experience

Tony Montgomery

A simple endogenous tryptamine can profoundly alter perception and self-modeling. The Birth Echo Hypothesis proposes that during a narrow perinatal window around delivery, a convergence of stress, sensory novelty, and neuromodulators biases encoding of high-salience sensorimotor templates. In adulthood, exogenous DMT may reconfigure brain dynamics via 5-HT2A and sigma-1 receptors, making these preverbal templates accessible as archetypal, emotionally intense, synesthetic content. DMT is framed as a co-modulator within an evolved perinatal regulatory ensemble. Testable predictions include adult DMT phenomenology showing perinatal-consistent motifs, neonatal EEG/fMRI state-space similarity to adult DMT states, and peri-parturient biospecimens revealing DMT-pathway marker co-variation. The hypothesis reframes psychedelic phenomenology as structural re-expression of early sensorimotor templates.

DOI: 10.31124/advance.175748232.23223560/v1

Psychedelic Therapy: A Primer for Primary Care Clinicians—5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT)

Burton J. Tabaac, Kenneth Shinozuka, Anne Weisman et al. preprint

5-MeO-DMT, a psychedelic found in toad venom and some plants, shows rapid antidepressant effects in early clinical trials. A Phase 2b trial reported that 57.5% of participants with treatment-resistant depression achieved remission within eight days. Other Phase 2a and 2b trials suggest it may reduce depressive symptoms more effectively than existing treatments like SSRIs. The substance appears low-risk in controlled settings, though most studies are small and only two double-blind randomized controlled trials have been conducted in clinical populations. Long-term effects need further study, and its possible link to near-death experiences remains debated.

DOI: 10.31234/osf.io/9gbkt_v1

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part III. N,N-dimethyltryptamine (DMT) and Ayahuasca

Kenneth Shinozuka, Burton J. Tabaac, Alejandro Arenas et al. preprint

DMT, the psychedelic in ayahuasca, is being studied for depression. In a double-blind, placebo-controlled trial, ayahuasca led to remission in 36% of patients with treatment-resistant depression within one week. A Phase IIa trial reported that 57% of patients with major depressive disorder experienced remission 12 weeks after a single dose of DMT. DMT is naturally produced in the body, but likely at insignificant levels. The idea that DMT is released during death remains unproven. Ayahuasca can cause temporary vomiting but appears generally safe. More research is needed on DMT's therapeutic and biological roles.

DOI: 10.31234/osf.io/2cteb

Therapeutic properties of ayahuasca component N,N-Dimethyltryptamine in a pre-clinical model of Parkinson's disease.

Experimental neurology September 1, 2026 Javier Calleja-Conde, Víctor Echeverry-Alzate, Marina Sanz-Sancristóbal et al.

In a preclinical model of Parkinson's disease, the compound N,N-dimethyltryptamine (DMT), the main psychoactive ingredient in ayahuasca, reduced neuroinflammation and preserved neurons in the nigrostriatal pathway. Treated animals also showed improvements in behavior. These results suggest DMT may have disease-modifying potential for Parkinson's disease, a progressive neurodegenerative disorder marked by loss of dopaminergic neurons and chronic inflammation, for which current treatments only relieve symptoms.

DOI: 10.1016/j.expneurol.2026.115822 Full text Dimethyltryptamine Neurodegeneration Neuroinflammation Parkinson +1

Beyond Monoamines: Ketamine, Esketamine, and Classic Psychedelics in the Treatment of Depression

Zenodo (CERN European Organization for Nuclear Research) July 17, 2026 Bartosz Niciński, Magdalena Kloc, Ewa Wiench, Natasza Millan, Aleksandra Blicharz, Wojciech Kozdraś, Lidia Kozaczko, Gabriela Szewczyk, Elżbieta Bukowczan, Alicja Zając, Damian Broda, Alicja Benecka

Major depressive disorder is a common and burdensome condition, and many patients do not fully recover after standard antidepressant treatment, prompting interest in rapid-acting interventions that target brain pathways beyond serotonin, norepinephrine, and dopamine. This review examines ketamine, esketamine, and classic psychedelics for depression, especially treatment-resistant depression. Ketamine and esketamine have the strongest evidence, with ketamine showing rapid antidepressant and anti-suicidal effects, and intranasal esketamine being the first NMDA receptor antagonist approved for treatment-resistant depression. Psilocybin-assisted therapy has shown promising results but remains investigational and requires a structured therapeutic framework. Evidence for LSD, DMT, and mescaline is preliminary. These treatments highlight the roles of glutamatergic modulation, serotonergic mechanisms, and neuroplasticity. Key unresolved issues include maintaining effects over time, identifying which patients benefit most, and safe delivery outside specialized settings.

DOI: 10.5281/zenodo.21406175 Serotonergic Ketamine Major depressive disorder Treatment-resistant depression +12

Clinical trials

All DMT trials →